Jpmorgan Chase & CO Celldex Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CLDX
# of Institutions
196Shares Held
63.8MCall Options Held
212KPut Options Held
176K-
Wellington Management Group LLP Boston, MA8.08MShares$205 Million0.05% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$119 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$94.9 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.39MShares$86 Million9.76% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$84.5 Million2.17% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.19B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...